1
|
Teng GS, Zhang YH, Wang Y, Du CX, Li YQ, Hu NB, Xiang GP, Shao ZH, Bai J. [Efficacy and safety of pegylated interferon alpha-2b for patients with myeloproliferative neoplasm]. Zhonghua Yi Xue Za Zhi 2023; 103:3645-3651. [PMID: 38018063 DOI: 10.3760/cma.j.cn112137-20231007-00654] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/30/2023]
Abstract
Objective: To evaluate the efficacy and safety of pegylated interferon alpha-2b (PEG-IFN-α2b) in the treatment of myeloproliferative neoplasm (MPN). Methods: Thirty-four MPN patients receiving PEG-IFN-α2b treatment in the Second Hospital of Tianjin Medical University from August 2019 to October 2022 were prospectively included. Among the patients, 9 were male and 25 were female, and the median age [M (Q1, Q3)] was 57 (19, 78) years. Patients' clinical characteristics were collected and the follow-up was performed. As of January 30, 2023, the follow-up period [M(Q1, Q3)] was 24 (16, 33) months. The efficacy, safety and changes in immune cell and cytokine levels after 12 and 24 months of treatment were analyzed. Results: During the follow-up period, 4 patients dropped out, and the efficacy was evaluable in 30 patients. Following 12 and 24 months of treatment, the complete hematologic response (CHR) rates were 57.1% (16/28) and 75.0% (18/24), respectively. The complete molecular response (CMR)+partial molecular response (PMR) rates were 27.3% (6/22) and 55.0% (11/20), respectively. The bone marrow histopathological overall response rates (ORR) were 34.6% (9/26) and 47.6% (10/21), respectively. At 12 and 24 months of treatment, the proportions of CD8+HLA-DR+T cells, effector T cell subpopulations, CD56bright natural killer (NK) cells, and plasmacytoid dendritic cells (pDC) were higher than the pre-treatment levels, while the proportion of CD56dim NK cells was lower than the pre-treatment level (all P<0.05). The levels of motif chemokine ligand 10 (CXCL10), tumor necrosis factor (TNF)-α and TNF-β in bone marrow all increased from those prior to treatment, while the levels of vascular endothelial growth factor (VEGF) and interleukin (IL-4) decreased from those prior to treatment (all P<0.05). Among hematological adverse reactions, white blood cells decrease [47% (16/34)] was observed with high incidence. Among non-hematological adverse reactions, asthenia [44.1% (15/34)] and transaminases increase [32.3% (11/34)] were observed with high incidences. Conclusions: PEG-IFN-α2b has high hematologic, molecular, and bone marrow histopathological response rates in the treatment of MPN. It can reduce malignant clone loads and regulate the immune microenvironment and is safe and well tolerated overall.
Collapse
Affiliation(s)
- G S Teng
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Y H Zhang
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Y Wang
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - C X Du
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Y Q Li
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - N B Hu
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - G P Xiang
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Z H Shao
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - J Bai
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| |
Collapse
|
2
|
Zhang YH, Teng GS, Ma JY, Hu X, Du CX, Wang Y, Hu NB, Li YQ, Shao ZH, Bai J. [Analysis of risk factors for thromboembolism in patients with JAK2 V617F gene mutation positive myeloproliferative neoplasms]. Zhonghua Yi Xue Za Zhi 2023; 103:3652-3657. [PMID: 38018064 DOI: 10.3760/cma.j.cn112137-20231007-00647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/30/2023]
Abstract
Objective: To analyze the risk factors of thrombosis in patients with JAK2V617F mutation positive myeloproliferative neoplasms (MPN). Methods: A total of 223 MPN patients with JAK2V617F mutation in the Second Hospital of Tianjin Medical University from September 2017 to May 2023 were retrospectively enrolled, including 111 males and 112 females, aged [M(Q1,Q3)] 57(21,66) years. According to the presence or absence of thromboembolism during follow-up, the patients were divided into thrombosis group (n=102) and non-thrombosis group (n=121). The clinical characteristics, laboratory characteristics, cytogenetics and other disease progression and survival of the two groups of patients were analyzed. As of March 31, 2023, the follow-up period [M (Q1, Q3)] was 6 (3, 10) years. The influencing factors of thrombosis in JAK2V617F positive MPN patients were analyzed by using the Cox risk model. Results: Among 223 JAK2V617F positive MPN patients, 144 were polycythemia vera (PV), 51 were essential thrombocythemia (ET) and 28 were primary myelofibrosis (PMF). The mutation rates of ASXL1 and BCORL1 genes in the thrombosis group were 19.6% (20/102) and 6.9% (7/102), respectively, which were higher than those in the non-thrombosis group [9.1% (11/121) and 0.8% (1/121)] (both P<0.05). The proportion of monocytes, C-reactive protein (CRP), interleukin-1β (IL)-1β, IL-8 and tumor necrosis factor-β (TNF-β) increased in the thrombosis group were higher than those in the non-thrombosis group (all P<0.05). Multivariate analysis showed that age≥60 years (HR=2.132, 95%CI: 1.376-3.303, P=0.001), history of thrombosis (HR=3.636, 95%CI: 2.121-6.202, P<0.001), ASXL1 mutation positive (HR=2.245, 95%CI: 1.093-3.231, P=0.022) and elevated TNF-β (HR=2.009, 95%CI: 1.113-3.624, P=0.021) were risk factors for thrombosis in JAK2V617F positive MPN patients. Conclusions: In addition to age, history of thrombosis and positive ASXL1 mutation, elevated TNF-β is also an influencing factor of thrombosis in JAK2V617F positive MPN patients. Intervention of inflammation may have a certain effect on the prevention and treatment of thrombosis.
Collapse
Affiliation(s)
- Y H Zhang
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - G S Teng
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - J Y Ma
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - X Hu
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - C X Du
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Y Wang
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - N B Hu
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Y Q Li
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Z H Shao
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - J Bai
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| |
Collapse
|
3
|
Peng L, Zhang YH, Teng GS, Du CX, Wang Y, Hu NB, Li YQ, Shao ZH, Bai J. [Clinical and laboratory features of SF3B1-mutated myeloproliferative neoplasms]. Zhonghua Yi Xue Za Zhi 2023; 103:3472-3477. [PMID: 37981774 DOI: 10.3760/cma.j.cn112137-20230928-00609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/21/2023]
Abstract
Objective: To explore the clinical and laboratory characteristics of SF3B1 gene mutations in myeloproliferative neoplasms (MPN) patients. Methods: The clinical data of 273 MPN patients who were diagnosed MPN and treated in the Second Hospital of Tianjin Medical University from November 2017 to March 2023 were retrospectively analyzed. There were 133 males and 140 females, with a median age M(Q1,Q3)of 56(46, 67) years. The molecular biology and cytogenetic characteristics were detected by second-generation sequencing (NGS) and R+G banding techniques, and the clinical and laboratory characteristics of patients with SF3B1 gene mutation were analyzed. Results: SF3B1 gene mutations were found in 13 patients (4.8%, 13/273).The types of SF3B1 mutations included missense (92.3%, 12/13) and nonsense mutations (7.7%, 1/13).Compared to the non-mutant cohort, patients in SF3B1 mutant cohort had older ages [68(51, 76) vs 56(45, 66)years,P=0.025], higher proportion of splenomegaly [46.2%(6/13) vs 15.8%(41/259),P=0.014]and secondary tumor [23.1%(3/13)vs 3.8%(10/260), P=0.018]with higher proportion of bone marrow blast [0.5%(0, 1.5%) vs 0(0, 0.5%),P=0.002] and lower hemoglobin[(104±36) vs (137±40) g/L,P=0.004] and hematocrit [31%(22%, 40%) vs 41%(35%, 52%),P=0.003]. All of the 10 patients in the SF3B1 mutant cohort whose ring sideroblast (RS) could be evaluated showed no RS formation. The overall survival, thrombosis-free survival and leukemia free survival of MPN patients in SF3B1 mutant cohort were 4.0 (2.0, 6.0), 2.0 (0.5, 4.5) and 4.0 (2.0, 6.0) years, respectively, while patients in the non-mutant cohort were 6.0 (3.0, 10.0), 5.0 (1.0, 8.0), 6.0 (3.0, 10.0) years, respectively, there were no statistical significance between two groups (Z=3.69, 1.66, 2.05, all P>0.05).The secondary tumor free survival of SF3B1 mutant cohort patients was 4.0 (2.0, 6.0) years, which was lower than that of non-mutant cohort patients [5.5 (3.0, 10.0) years, Z=18.18, P<0.001). Conclusions: MPN patients with SF3B1 gene mutations are older, more prone to splenomegaly and secondary tumors. They also have a higher proportion of bone marrow blast, lower hemoglobin and hematocrit, and show no RS formation.
Collapse
Affiliation(s)
- L Peng
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Y H Zhang
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - G S Teng
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - C X Du
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Y Wang
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - N B Hu
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Y Q Li
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Z H Shao
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - J Bai
- Department of Hematology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China
| |
Collapse
|
4
|
Li YQ, Zhang YH, Teng GS, Hu NB, Wang Y, Duan YF, Bai J. [Clinical features of hemophagocytic lymphohistiocytosis associated with myeloid neoplasms: a report of 8 cases]. Zhonghua Xue Ye Xue Za Zhi 2023; 44:949-951. [PMID: 38185527 PMCID: PMC10753253 DOI: 10.3760/cma.j.issn.0253-2727.2023.11.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 03/19/2023] [Indexed: 01/09/2024]
Affiliation(s)
- Y Q Li
- Department of Hematology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Y H Zhang
- Department of Hematology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - G S Teng
- Department of Hematology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - N B Hu
- Department of Hematology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Y Wang
- Department of Hematology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - Y F Duan
- Department of Hematology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| | - J Bai
- Department of Hematology, Second Hospital of Tianjin Medical University, Tianjin 300211, China
| |
Collapse
|
5
|
Shi ZX, Zhang PH, Li B, Fang LH, Xu ZF, Qin TJ, Liu JQ, Hu NB, Pan LJ, Qu SQ, Liu D, Xiao ZJ. [Pathological characteristics of megakaryocytes in myeloproliferative neoplasms and their correlation with driver gene mutations]. Zhonghua Xue Ye Xue Za Zhi 2021; 41:798-805. [PMID: 33190435 PMCID: PMC7656079 DOI: 10.3760/cma.j.issn.0253-2727.2020.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the pathological characteristics of megakaryocytes in myeloproliferative neoplasms(MPN)and their correlations with driver gene mutations. Methods: Trephine specimens administered for 160 patients with MPN from February 2012 to October 2017 were reevaluated according to the World Health Organization(WHO)'s(2016)diagnostic criteria. Results: This cohort of patients included 72(45.0%)men, with the median age of 59(range, 13-87)years, comprising 39 with polycythemia vera(PV), 33 with essential thrombocythemia(ET), 37 with prefibrotic/early-primary myelofibrosis(pre-PMF), 37 with overt PMF, 1 with post-ET MF, 2 with post-PV MF, and 11 with MPN-unclassifiable(MPN-U)after the re-diagnosis. With PV, ET, pre-PMF, and overt PMF changes, proportions of dense clusters, hypolobulated nuclei, and naked nuclei of megakaryocytes gradually increased, whereas erythropoiesis gradually decreased. Proportions of reticulin, collagen, and osteosclerosis grades of ≥1 also increased. Dense clusters, hypolobulated nuclei, and naked nuclei of megakaryocytes were negatively correlated with erythropoiesis and positively correlated with granulopoiesis and fibrosis. In patients with pre- and overt PMF, dense clusters and naked nuclei of megakaryocytes were positively correlated with fibrosis. Patients with JAK2V617F MPN had significantly increased erythropoiesis(P=0.022). Patients with CALR-mutated MPN were characterized by increased loose and dense clusters; paratrabecular distribution and naked nuclei of megakaryocytes(P=0.055, P=0.002, P=0.018, P=0.008); and increased reticulin, collagen, and osteosclerosis(P=0.003, P<0.001, P=0.001). In patients with pre- and overt PMF, patients with JAK2V617F had increased cellularity(P=0.037). CALR-mutated patients had increased dense clusters and giant sizes of megakaryocytes, collagen, and osteosclerosis(P=0.055, P=0.059, P=0.011, P=0.046). Conclusion: Megakaryocytes showed abnormal MPN morphology and distribution, which were related to fibrosis. CALR mutation was probably associated with abnormal morphology and distribution of megakaryocytes and fibrosis.
Collapse
Affiliation(s)
- Z X Shi
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - P H Zhang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - B Li
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - L H Fang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Z F Xu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - T J Qin
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - J Q Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - N B Hu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - L J Pan
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S Q Qu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - D Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Z J Xiao
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| |
Collapse
|
6
|
Huang HJ, Li B, Qin TJ, Xu ZF, Hu NB, Pan LJ, Qu SQ, Liu D, Zhang YD, Xiao ZJ. [Molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes]. Zhonghua Xue Ye Xue Za Zhi 2021; 41:723-730. [PMID: 33113603 PMCID: PMC7595862 DOI: 10.3760/cma.j.issn.0253-2727.2020.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes (MDS) . Methods: 112-gene targeted sequencing was conducted to detect RAS mutations in 776 patients with newly diagnosed primary MDS from December 2011 to December 2018. The mutual exclusivity and co-occurrence in gene mutations and clonal architecture were explored. Moreover, the prognostic significance of RAS mutations in MDS was analyzed. Results: RAS gene mutations were found in 52 (6.7% ) cases, 38 (4.9% ) of whom harbored NRAS mutation, 18 (2.3% ) KRAS mutation, and 4 (0.5% ) both NRAS and KRAS mutations. All the NRAS mutations and 65% of the KRAS mutations were located in codons 12, 13, and 61. PTPN11, FLT3, U2AF1, RUNX1, WT1, ETV6, and NPM1 mutations were enriched in patients with RAS mutations (Q<0.05) . Around 80% of RAS mutations represented subclonal lesions in patients who harbored at least two different mutations. Patients with RAS mutations were more frequently diagnosed with MDS with excess blast (MDS-EB) (82.7% vs. 35.2% , P<0.001) and had higher levels of white blood cell count (4.33×10(9)/L vs. 2.71×10(9)/L, P<0.001) , neutrophil absolute count (2.13×10(9)/L vs. 1.12×10(9)/L, P<0.001) , and bone marrow blast percentage (7% vs. 2% , P<0.001) but lower levels of platelet count (48×10(9)/L vs. 62×10(9)/L, P=0.048) . RAS mutations were correlated with higher-risk categories in the Revised International Prognostic Scoring System (IPSS-R) (71.1% vs. 37.9% , P<0.001) . The median overall survival of patients with NRAS mutations was shorter than the others (P=0.011) , while the significance was lost in the multivariable model. Conclusion: RAS gene mutations always occurred in the late-stage MDS and co-occurred with other signal transduction- and transcription factor-related gene mutations. PTPN11, a RAS pathway-related gene, is an independent poor prognostic factor in MDS patients.
Collapse
Affiliation(s)
- H J Huang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - B Li
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - T J Qin
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Z F Xu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - N B Hu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - L J Pan
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - S Q Qu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - D Liu
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Y D Zhang
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| | - Z J Xiao
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
| |
Collapse
|
7
|
Cai YN, Xu ZF, Li B, Qin TJ, Pan LJ, Qu SQ, Hu NB, Liu D, Huang HJ, Shi ZX, Zhang YD, Xiao ZJ. [Features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts]. Zhonghua Xue Ye Xue Za Zhi 2020; 41:379-386. [PMID: 32536134 PMCID: PMC7342062 DOI: 10.3760/cma.j.issn.0253-2727.2020.05.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Objective: To explore the features and clinical significance of gene mutations in patients with myelodysplastic syndromes with ring sideroblasts (MDS-RS) . Methods: A total of 255 newly diagnosed primary MDS-RS patients were retrospectively reviewed from our center from January2001 to June 2019. SF3B1 gene mutations were detected by Sanger sequencing in 129 patients, and next generation sequencing (NGS) was performed in the other 126 patients using a set of selected 112-genes. Results: A total of 193 (75.7%) patients presented with SF3B1 mutation, predominantly mutant at amino acid position 700 (K700E) (n=147, 76.2%) . Non-SF3B1 gene mutations were TET2 (16.7%) , ASXL1 (14.3%) , U2AF1 (11.1%) , TP53 (7.9%) , SETBP1 (6.3%) , and RUNX1 (6.3%) . RS 5%-<15% patients had a higher SETBP1 mutation frequency than RS≥15% patients (21.4% vs 4.5%, P=0.044) . Mutation frequencies of other genes were similar in both groups (all P>0.05) . SF3B1 variant allele frequencies (VAF) had positive correlation with marrow RS percentage but without statistical significance in RS 5%-<15% group (P=0.078, r=0.486) . SF3B1 mutant patients presented with higher marrow RS percentage compared with wild-type patients[40.0% (15.0%-80.0%) vs 25.5% (15.0%-82.0%) , P<0.001], and SF3B1 VAF positively correlated with RS percentage (P=0.009, rs=0.261) in RS≥15% group. Age, ANC, PLT, mean RBC corpuscular volume, RS percentage, IPSS-R cytogenetics, and IPSS-R risk score were significantly different between patients with SF3B1 mutations and wild-type SF3B1 (all P<0.05) . Multivariable survival analyses adjusted by age and IPSS-R cytogenetics revealed that SF3B1 mutation was an independent favorable prognostic factor (HR=0.265, 95% CI 0.077-0.917, P=0.036) , and TP53 mutation was an adverse variable independent of SF3B1 mutation (HR=6.272, 95% CI 1.725-22.809, P=0.005) . According to the mutant status of SF3B1 and TP53, MDS-RS patients were categorized into 4 groups, namely, with SF3B1 and TP53 mutation, with wild-type SF3B1 and TP53, with wild-type SF3B1 but TP53 mutation, and with SF3B1 mutation but wild-type TP53. There was a significant difference for OS among these 4 groups (P<0.001) . The former 3 groups showed no significant difference in OS in multiple comparisons. However, the SF3B1 mutation but wild-type TP53 group had a better OS than wild-type SF3B1 but TP53 mutation group and wild-type SF3B1 and TP53 group, whereas a similar OS compared with SF3B1 and TP53 mutation group. Conclusion: SF3B1 mutations were prevalent in MDS-RS patients with the most common mutation at amino acid position 700 (K700E) . SF3B1 mutation was an independent favorable prognostic variable, whereas TP53 mutation was an independent adverse variable. SF3B1 mutation could coordinate with TP53 mutation for more sophisticated prognosis stratification in MDS-RS patients.
Collapse
Affiliation(s)
- Y N Cai
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Tianjin 300020, China
| | - Z F Xu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Tianjin 300020, China
| | - B Li
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Tianjin 300020, China
| | - T J Qin
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Tianjin 300020, China
| | - L J Pan
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Tianjin 300020, China
| | - S Q Qu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Tianjin 300020, China
| | - N B Hu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Tianjin 300020, China
| | - D Liu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Tianjin 300020, China
| | - H J Huang
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Tianjin 300020, China
| | - Z X Shi
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Tianjin 300020, China
| | - Y D Zhang
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Tianjin 300020, China
| | - Z J Xiao
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Centre for Blood Diseases, Tianjin 300020, China
| |
Collapse
|
8
|
Shi ZX, Qin TJ, Xu ZF, Huang HJ, Li B, Qu SQ, Hu NB, Pan LJ, Liu D, Cai YN, Zhang YD, Xiao ZJ. [Mean corpuscular volume ≤100 fl was an independent prognostic factor in patients with myelodysplastic syndrome and bone marrow blast<5 percent]. Zhonghua Xue Ye Xue Za Zhi 2020; 41:28-33. [PMID: 32023751 PMCID: PMC7357904 DOI: 10.3760/cma.j.issn.0253-2727.2020.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
目的 探讨平均红细胞体积(MCV)对骨髓增生异常综合征(MDS)预后的影响。 方法 收集2009年12月至2017年12月我中心新诊断、无红细胞输注史的321例原发性MDS患者,回顾性分析MCV水平对整体及不同骨髓原始细胞水平患者总生存(OS)期的影响。 结果 全部患者按照MCV水平高低分为MCV≤100 fl组(148例)和MCV>100 fl组(173例)。MCV≤100 fl组患者中位OS时间为27(95%CI 19~35)个月,MCV>100 fl组患者中位OS时间为72(95%CI 5~139)个月,差异有统计学意义(P<0.001)。亚组分析示,在骨髓原始细胞<5%的患者中,MCV≤100 fl患者的中位OS期较MCV>100 fl者显著缩短(P=0.002);而在骨髓原始细胞≥5%的患者中,MCV水平对OS的影响不显著(P=0.078)。在纳入其余临床指标及基因突变校正后,MCV≤100 fl仍为骨髓原始细胞<5%患者的独立不良预后因素(HR=1.890,95%CI 1.007~3.548,P=0.048)。对不同MCV水平骨髓原始细胞<5%的MDS患者的临床及实验室指标进行分析,结果显示MCV≤100 fl组患者外周血HGB高于MCV>100 fl组[90(42~153)g/L对78.5(28~146)g/L,P=0.015],IPSS-R高危/极高危组比例及IPSS-R染色体核型分组差/很差比例明显高于MCV>100 fl组,差异有统计学意义(28.8%对10.8%,P=0.003;24.7%对12.9%,P=0.049)。MCV≤100 fl组患者平均基因突变数目较MCV>100 fl组多(0.988个对0.769个,P=0.064),SF3B1突变较MCV>100 fl组少见(4.7%对15.4%,P=0.018)。 结论 MCV≤100 fl为骨髓原始细胞<5%的MDS患者独立于基因突变及其他临床指标的预后不良因素。
Collapse
Affiliation(s)
- Z X Shi
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - T J Qin
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Z F Xu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - H J Huang
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - B Li
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - S Q Qu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - N B Hu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - L J Pan
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - D Liu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Y N Cai
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Y D Zhang
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| | - Z J Xiao
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin 300020, China
| |
Collapse
|
9
|
Liu D, Xu ZF, Qin TJ, Li CW, Hu NB, Pan LJ, Qu SQ, Li B, Xiao ZJ. [Analysis of clinical characteristics, treatment response rate and survival of 77 myelodysplastic syndrome patients with del (5q) syndrome]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:895-900. [PMID: 31856436 PMCID: PMC7342376 DOI: 10.3760/cma.j.issn.0253-2727.2019.11.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
目的 探讨符合WHO(2016)诊断分型标准的骨髓增生异常综合征(MDS)5q−综合征患者的临床特征、来那度胺(LEN)疗效和生存情况。 方法 回顾性分析2008年1月至2018年4月于中国医学科学院血液病医院就诊的77例符合WHO(2016)诊断分型标准的MDS 5q−综合征患者临床资料,比较单纯5q−与5q−伴1个非−7/7q−的其他染色体异常(ACA)患者临床特征、疗效及生存情况,并比较LEN与非LEN药物治疗的疗效与生存情况。 结果 77例患者中,单纯5q−者64例,5q−伴ACA者13例,确诊时5q−伴ACA患者的中位年龄显著低于单纯5q−患者[58(29~64)岁对63(31~82)岁,z=2.164,P=0.030]。5q−伴ACA患者CD41免疫组化染色小巨核细胞(直径≤40 µm)检出率(91.7%,11/12)显著高于单纯5q−患者(60.0%,33/55)(P=0.046)。可评估LEN疗效的29例患者中,单纯5q−患者(19例)与5q−伴ACA患者(10例)血液学总反应率(78.9%对80.0%)、血液学完全缓解(CR)率(57.9%对60.0%)、细胞遗传学反应(CyR)率[69.2%(9/13)对66.7%(4/6)]、完全细胞遗传学反应(CCyR)率[61.5%(8/13)对33.3%(2/6)]相当。单纯5q−与5q−伴ACA患者中位总生存(OS)时间差异无统计学意义(62个月对78个月,P=0.313)。29例LEN组患者的血液学总反应率(79.3%对36.0%)、CR率(58.6%对8.0%)、CyR率[68.4%(13/19)对11.1%(1/9)]、CCyR率[52.6%(10/19)对0(0/9)]均高于非LEN组患者(25例),但两组患者中位OS时间差异无统计学意义(78个月对62个月,P=0.297)。 结论 单纯5q−与5q−伴ACA患者临床特征大体相似,两组患者LEN疗效、中位OS时间无明显差异。LEN治疗5q−综合征患者的疗效肯定,优于非LEN药物。
Collapse
Affiliation(s)
- D Liu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Tianjin 300020, China
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Huang HJ, Shi ZX, Li B, Qin TJ, Xu ZF, Zhang HL, Fang LW, Hu NB, Pan LJ, Qu SQ, Liu D, Cai YN, Zhang YD, Xiao ZJ. [Clinical implications and prognostic value of TP53 gene mutation and deletion in patients with myelodysplastic syndromes]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:215-221. [PMID: 30929389 PMCID: PMC7342541 DOI: 10.3760/cma.j.issn.0253-2727.2019.03.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
目的 探讨伴TP53基因异常骨髓增生异常综合征(MDS)患者的临床特征及预后。 方法 回顾性分析2009年10月至2017年12月中国医学科学院血液病医院新诊断的584例原发性MDS患者临床资料,采用包含112个血液肿瘤相关基因的靶向测序技术进行突变分析,并采用间期荧光原位杂交(FISH)技术检测TP53基因缺失。分析TP53基因突变和(或)缺失与临床特征之间的关系及其对患者总生存(OS)的影响。 结果 42例(7.2%)伴TP53基因异常,其中单纯基因突变31例(5.3%),单纯基因缺失8例(1.4%),同时伴有突变和缺失3例(0.5%)。34例伴TP53基因突变患者中共检测到37个TP53突变,其中35个位于DNA结合结构域(第5~8号外显子),1个位于第10号外显子,1个为剪切位点突变。伴TP53基因异常组的平均基因突变数目(2.52个)显著高于无异常组(1.96个)(z=−2.418,P=0.016)。伴TP53基因异常患者的中位年龄[60(21~78)岁]高于无异常患者[52(14~83)岁](z=−2.188,P=0.029);伴TP53基因异常组中复杂核型比例、IPSS较高危组(中危-2及高危)比例显著高于无异常组(P值均<0.001)。伴TP53基因异常组的中位OS期[13(95%CI 7.57~18.43)个月]较无异常组(未达到)显著缩短(χ2=12.342,P<0.001),但多因素模型纳入复杂核型进行校正后,TP53突变不再是独立预后因素。 结论 伴TP53基因异常MDS患者中基因突变较基因缺失常见,突变位点主要分布于DNA结合结构域。TP53基因异常与复杂核型相关,且常与多个基因突变相伴出现。在多因素模型纳入复杂核型校正后,TP53基因异常则不再是独立的预后因素。
Collapse
Affiliation(s)
- H J Huang
- Institute of Hematology and Blood Diseases Hospital CAMS & PUMC, The State Key Laboratory of Experimental Hematology, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Xu ZF, Qin TJ, Zhang HL, Fang LW, Hu NB, Pan LJ, Qu SQ, Li B, Yan X, Shi ZX, Huang HJ, Liu D, Cai YN, Zhang YD, Zhang PH, Xiao ZJ. [A study of clinical characteristics and prognosis of primary myelofibrosis patients with thrombocytopenia in varied degrees]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:12-16. [PMID: 30704222 PMCID: PMC7351693 DOI: 10.3760/cma.j.issn.0253-2727.2019.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
目的 探讨不同血小板水平原发性骨髓纤维化(PMF)患者的临床特征及其预后。 方法 对1990年5月1日至2017年4月30日在中国医学科学院血液病医院就诊的1 305例PMF患者进行回顾性分析。 结果 1 305例PMF患者中,重度血小板减少(PLT<50×109/L)、轻度血小板减少[PLT(50~99)×109/L]、无血小板减少患者(PLT≥100×109/L)分别为320例(24.5%)、198例(15.2%)和787例(60.3%)。在血小板计数越低的组别中,HGB<100 g/L患者比例、WBC<4×109/L患者比例和外周血原始细胞≥3%患者比例、异常染色体核型患者比例和预后不良染色体核型患者比例越高(P<0.001,P<0.001,P=0.004,P<0.001,P<0.001),JAK2V617F突变阳性率越低(P<0.001)。血小板计数与脾肿大、HGB、WBC呈正相关(P值均<0.001,相关系数分别为0.131、0.445、0.156),与体质性症状和外周血原始细胞比例呈负相关(P值分别为0.009、0.045,相关系数为−0.096、−0.056)。重度血小板减少、轻度血小板减少、无血小板减少组患者中位生存时间分别为32、67、89个月(P<0.001)。血小板减少程度分组[HR=1.693(95%CI 1.320~2.173),P<0.001]和动态国际预后积分系统(DIPSS)预后分级[HR=2.051(95%CI 1.511~2.784),P<0.001]均为PMF患者独立不良预后因素。 结论 血小板计数越低的PMF患者出现贫血、白细胞减少和外周血原始细胞比例增高的比例越高、临床表现越重、预后越差,临床上应采取更加积极的治疗措施。
Collapse
Affiliation(s)
- Z F Xu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, The State Key Laboratory of Experimental Hematology, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Xu ZF, Qin TJ, Zhang HL, Fang LW, Pan LJ, Hu NB, Qu SQ, Li B, Xiao ZJ. [Ruxolitinib combined with prednisone, thalidomide and danazol for treatment of myelofibrosis: a pilot study]. Zhonghua Xue Ye Xue Za Zhi 2019; 40:24-28. [PMID: 30704224 PMCID: PMC7351690 DOI: 10.3760/cma.j.issn.0253-2727.2019.01.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To evaluate the efficacy and tolerability of ruxolitinib combined with prednisone, thalidomide and danazol for treatment of in myelofibrosis (MF). Methods: Patients of MF according to the WHO 2016 criteria, received ruxolitinib (RUX) combined with prednisone, thalidomide and danazol (PTD). The response, changes of blood counts and adverse events were evaluated. Results: Six PMF and one post-ET MF patients were enrolled. Four patients presented JAK2V617F mutation, one CALR mutation, one MPL mutation, one triple-negative. Responses per IWG-MRT criteria were clinical improvement in 5 patients, stable disease in 2 ones, spleen response in 6 ones. All of 7 patients were symptomatic responses, four patients achieved at least 50% improvement from baseline on MPN-SAF TSS. Three patients initially treated with RUX alone, all of 3 patients experienced treatment-associated anemia and thrombocytopenia. Then these 3 patients received RUX combined with PTD, both hemoglobin and platelet increased significantly. Four patients initially treated with RUX combined with PTD. Increased levels of hemoglobin and platelet were seen in all of 7 patients received RUX combined with PTD with maximum increased hemoglobin of 30(18-54) g/L and maximum increased platelets of 116(13-369)×10(9)/L, respectively from baseline. The treatment dose of RUX increased due to improved platelet count in 3 patients. The frequent non-hematologic adverse events grade 1-2 were constipation, abdominal distension, crura edema and increased ALT. Conclusions: RUX combined with PTD for treatment of MF may modulate initial hematologic toxicity observed when RUX alone, and may increase response due to improved levels of hemoglobin or platelet.
Collapse
Affiliation(s)
- Z F Xu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, The State Key Laboratory of Experimental Hematology, Tianjin 300020, China
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Qu SQ, Qin TJ, Xu ZF, Zhang Y, Jia YJ, Ai XF, Zhang HL, Fang LW, Hu NB, Pan LJ, Li B, Liu JQ, Ru K, Xiao ZJ. [Targeted sequencing analysis of hyper-eosinophilic syndrome and chronic eosinophilic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2018; 39:501-506. [PMID: 30032569 PMCID: PMC7342916 DOI: 10.3760/cma.j.issn.0253-2727.2018.06.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/03/2018] [Indexed: 11/05/2022]
Abstract
Objective: Analysis of the molecular characteristics of eosinophilia. Methods: Targeting sequence to 24 patients with chronic eosinophilic leukemia (CEL) with rearrangement of PDGFRA, PDGFRB, or FGFR1 and 62 patients with hyper-eosinophilic syndrome (HES). Mutation annotation and analysis of amino acid mutation using authoritative databases to speculate on possible pathogenic mutation. Results: Thirty-seven kinds of clonal variant were detected from 17 patients with CEL, no recurrent mutation site and hot spot region were found. No pathogenic mutation was detected in 19 patients with PDGFRA rearrangement, but pathogenic mutations of ASXL1, RUNX1 and NRAS were detected from 2 patients with FGFR1 rearrangement who progressed to acute myeloid leukemia and 1 patient with PDGFRB rearrangement who progressed to T lymphoblastic lymphoma, respectively. One hundred and two kinds of clonal abnormalities were detected in 49 patients with HES. The main hot spot mutation regions included: CEBPA Exon1, TET2 Exon3, ASXL1 Exon12, IDH1 Y208C, and FGFR3 L164V. CRRLF2 P224L and PDGFRB R370C point mutations were detected separately in 2 patients with HES who treated with imatinib monotherapy and achieved hematologic remission. Conclusion: The pathogenesis of CEL with PDGFRA, PDGFRB or FGFR1 rearrangement is usually single, and the progression of the disease may involve other driver mutation. A variety of genes with hot mutation regions may be involved in the pathogenesis of HES, and some mutation sites are sensitive to tyrosine kinase inhibitors.
Collapse
Affiliation(s)
- S Q Qu
- Institute of Hematology and Blood Diseases Hospital, Chinese Academe of Medical Sciences, The State Key Laboratory of Experimental Hematology, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Luo XP, Xu ZF, Qin TJ, Zhang Y, Zhang HL, Fang LW, Pan LJ, Hu NB, Qu SQ, Li B, Xiao ZJ. [Analysis of the impact of decitabine treatment cycles on efficacy and safety in patients of myelodysplastic syndrome-refractory anemia with excess blasts]. Zhonghua Xue Ye Xue Za Zhi 2018; 37:870-875. [PMID: 27801319 PMCID: PMC7364885 DOI: 10.3760/cma.j.issn.0253-2727.2016.10.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
目的 评估地西他滨治疗骨髓增生异常综合征(MDS)难治性贫血伴有原始细胞过多(RAEB)患者的疗效和不良反应与治疗疗程数的关系。 方法 2008年12月至2016年3月中国医学科学院血液病医院MDS诊疗中心共有56例RAEB患者接受了地西他滨20 mg·m−2·d−1×5 d方案治疗,回顾性分析其临床特征、疗效、疗效影响因素及不良反应。 结果 RAEB-1 25例,RAEB-2 31例。中位治疗3(1~15)个疗程。总有效[完全缓解(CR)+骨髓完全缓解(mCR)+血液学改善(HI)]率为67.9%(38/56),其中10例(17.8%)CR, 8例(14.3%)mCR但无HI,17例(30.4%)mCR同时有HI, 3例(5.4%)单纯HI。中位随访7.9(1.0~56.3)个月,中位生存期为21.1(95%CI 16.0~26.1)个月。RAEB-1患者的疗效(总有效率为88.0%)显著优于RAEB-2患者(总有效率为51.6%)(P=0.004),多因素分析证实其为影响疗效的独立预后因素(OR=6.03,95%CI 1.39~26.09,P=0.016)。地西他滨治疗有效的38例患者中,37例(97.4%)在1~2个疗程起效,25例(65.8%)在2个疗程内达到最佳疗效,37例(97.4%)在4个疗程内达最佳疗效。主要不良反应为3级以上血细胞减少及感染,在治疗早期(第1~2疗程)中较常见,治疗有效后随疗程增加,发生率逐渐下降,其他非血液学不良反应发生率低。 结论 地西他滨标准剂量5天方案治疗RAEB疗效肯定。治疗有效患者常在第1~2个疗程起效,4个疗程内达最佳疗效。主要不良反应为血细胞减少及感染,常见于前2个疗程,起效后后续疗程不良反应发生率显著降低。
Collapse
Affiliation(s)
- X P Luo
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Li B, Wang JY, Liu JQ, Shi ZX, Peng SL, Huang HJ, Qin TJ, Xu ZF, Zhang Y, Fang LW, Zhang HL, Hu NB, Pan LJ, Qu SQ, Xiao ZJ. [Gene mutations from 511 myelodysplastic syndromes patients performed by targeted gene sequencing]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:1012-1016. [PMID: 29365392 PMCID: PMC7342197 DOI: 10.3760/cma.j.issn.0253-2727.2017.12.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/15/2017] [Indexed: 12/20/2022]
Abstract
Objective: To study the characteristics of gene mutations in Chinese myelodysplastic syndromes (MDS) patients. Methods: A total of 511 Chinese patients with MDS performed 112-gene targeted sequencing were retrospectively analyzed. Results: Eighty-three distinct mutant genes were found in 511 patients with MDS. Amongst these, the most frequent mutations was associated with epigenetics (50%) , followed by spliceosome (37%) , signal transduction (34%) , transcription factors (24%) and cell cycle/apoptosis (17%) . 439 subjects (86%) had at least one gene mutation. The mean number of mutations in refractory anemia with unilineage dysplasia (RCUD) was 1.25, refractory anemia with multilineage dysplasia (RCMD) was 1.73, refractory anemia with ring sideroblasts (RARS) was 2.79, refractory anemia with excess blasts-1 (RAEB-1) was 2.22, RAEB-2 was 2.34, MDS with isolated 5q- was 2.67, MDS, unclassified (MDS-U) was 2.00. U2AF1 mutant subjects were more likely to have isolated+8[Q<0.001, OR=4.42 (95% CI 2.23-8.68) ]and less likely to have complex karyotypes[Q=0.005, OR=0.22 (95% CI 0.04-0.72) ]. According to the number of gene mutations, all subjects were categorized into three groups, namely group with 0-1 mutation, with 2 mutations and with three or more mutations. There was a significant difference in overall survival (OS) among three groups (P=0.041) . Conclusion: About 90% patients with MDS have at least one gene mutation. Genes associated with epigenetics and spliceosome are most common mutated genes in MDS. The increased numbers of gene mutations accompany with disease evolution and associate with poor prognosis.
Collapse
Affiliation(s)
- B Li
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, The State Key Laboratory of Experimental Hematology, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Xu ZF, Li B, Liu JQ, Li Y, Ai XF, Zhang PH, Qin TJ, Zhang Y, Wang JY, Xu JQ, Zhang HL, Fang LW, Pan LJ, Hu NB, Qu SQ, Xiao ZJ. [Prognostic value of JAK2, MPL and CALR mutations in Chinese patients with primary myelofibrosis]. Zhonghua Xue Ye Xue Za Zhi 2017; 37:576-80. [PMID: 27535857 PMCID: PMC7364995 DOI: 10.3760/cma.j.issn.0253-2727.2016.07.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
目的 评价JAK2、MPL和CALR基因突变在中国原发性骨髓纤维化(PMF)患者中的预后意义。 方法 回顾性分析402例PMF患者的临床资料及JAK2、MPL和CALR基因突变,应用Kaplan-Meier、Log-rank和Cox回归模型进行相关预后因素分析。 结果 402例PMF患者中男209例,女193例,中位年龄55(15~89)岁。JAKV617F基因突变189例(47.0%),MPLW515基因突变13例(3.2%),CALR基因突变81例(20.1%)[1型突变30例(37.0%),2型突变48例(59.3%),少见型突变3例(3.7%)],119例(29.6%)未检测到JAK2、MPL和CALR基因突变。单因素分析显示,2型CALR突变或未检测到JAK2、MPL和CALR基因突变的患者中位生存期(74个月)短于检测到JAK2、MPL或1型及少见型CALR基因突变的患者(168个月)[HR=2.990(95% CI 1.935~4.619),P <0.001]。因此,将基因突变类型分为预后不良组(2型CALR突变和未检测到JAK2、MPL和CALR基因突变)和预后良好组(JAKV617F、MPLW515、1型及少见型CALR基因突变)。经多因素分析提出了中国PMF患者的动态国际预后积分系统(DIPSS-Chinese)分子预后积分系统,各参数赋值如下:DIPSS-Chinese低危组0分,中危组1分,高危组2分,2型CALR突变或未检测到JAK2、MPL和CALR基因突变积1分。402例患者中,低危组(0分)132例(32.8%),中危-1组(1分)143例(35.6%),中危-2组(2分)106例(26.4%),高危组(3分)21例(5.2%)。低危组中位生存时间未达到,中危-1组为156(95% CI 117~194)个月,中危-2组为60(95% CI 28~91)个月,高危组为22(95% CI 10~33)个月,总生存差异具有统计学意义(P<0.001)。DIPSS-Chinese分子预后积分系统较DIPSS-Chinese有更准确的预测能力(−2 log似然比分别为855.6和869.7,P=0.005)。 结论 在中国PMF患者中,2型CALR突变和未检测到JAK2、MPL和CALR突变是独立的不良预后因素,DIPSS-Chinese分子预后积分系统有更好的预测价值。
Collapse
Affiliation(s)
- Z F Xu
- Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, the State Key Laboratory of Experimental Hematology, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Cui YJ, Jiang Q, Liu JQ, Li B, Xu ZF, Qin TJ, Zhang Y, Cai WY, Zhang HL, Fang LW, Pan LJ, Hu NB, Qu SQ, Xiao ZJ. [The clinical characteristics, gene mutations and prognosis of chronic neutrophilic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2017; 38:28-32. [PMID: 28219221 PMCID: PMC7348402 DOI: 10.3760/cma.j.issn.0253-2727.2017.01.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Indexed: 11/14/2022]
Abstract
Objective: To investigate the clinical manifestation, cytogenetics, gene mutations and prognostic factors of chronic neutrophilic leukemia (CNL) . Methods: 16 CNL cases, according to WHO (2016) -definition, were reviewed retrospectively. Identifications of the CSF3R, ASXL1, SETBP1, CALR and MPL mutations were performed by direct sequencing. JAK2 V617F mutation was detected by AS-PCR. Results: Of the 16 CNL patients, the median age was 64 (43-80) years with a male predominance of 75% (12/16) . The median hemoglobin was 114 (81-154) g/L, with median WBC of 41.20 (26.05-167.70) (10(9)/L and median PLT of 238 (91-394) ×10(9)/L.The median level of marrow fibrosis (MF) was 1 (0-3) degree. There was no other cytogenetic abnormalities except t (1;7) (p32;q11) , +21 and 14ps+ for each. All the 16 CNL patients harbored CSF3R T618I mutation. ASXL1 mutations were identified in 81% (13/16) , while SETBP1 mutations were confirmed in 63% (10/16) . The CALR K385fs*47 mutation was found. There was no mutation in JAK2 V617F or MPL in the above 16 patients. The median overall survival (OS) of patients presented with WBC≥50×10(9)/L at diagnosis (11 months) was significantly shorter than of WBC<50×10(9)/L (39 months, P=0.005) . Conclusion: CSF3R T618I mutation was specific for CNL. The median OS of CNL patients was 24 months, and WBC≥50×10(9)/L at diagnosis was an unfavorable prognostic factor.
Collapse
Affiliation(s)
- Y J Cui
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, The State Key Laboratory of Experimental Hematology, Tianjin 300020, China
| | | | | | | | | | | | | | | | | | | | | | | | | | - Z J Xiao
- Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, The State Key Laboratory of Experimental Hematology, Tianjin 300020, China
| |
Collapse
|